Mesoblast - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeMesoblast
Mesoblast logo

Mesoblast

0 followers

MESO

Performance

About Mesoblast

Mesoblast is an innovative biotechnology company specializing in the development and commercialization of allogeneic cellular medicines aimed at treating serious inflammatory diseases that currently have high unmet medical needs. Headquartered in Australia and listed on both the ASX and Nasdaq, the company is advancing several Phase 3 therapies, including RYONCIL™ for acute graft versus host disease, Remestemcel-L for COVID-19 related acute respiratory distress syndrome, REVASCOR® for chronic heart failure, and MPC-06-ID for chronic low back pain. With an extensive patent portfolio and rigorous research protocols, Mesoblast is committed to ensuring the safety and efficacy of its products for patients globally.

Recent News

Recent Deals

No recent deals for this company.

Key Team Members

Silviu Itescu

Chief Executive Officer (Executive Director)

Eric Rose

Chief Medical Officer (Executive Director)

Key Facts

HQ Location

Melbourne, Australia

Founded

2004

Employees

51 - 200

Status

Public

Website

https://mesoblast.com